Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

Sanofi

Status and phase: Completed; Phase 4

Conditions: Rhinitis, Allergic, Perennial

Treatments: Drug: Fexofenadine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00741897

M016455C_4001

Details and patient eligibility

About

To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.

Enrollment: 264 patients

Sex: All

Ages: 6 to 11 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Children who manifest allergic rhinitis symptoms such as sneezing, rhinorrhea, itchy nose/palate/throat and/or itchy/watery/red eyes.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

264 participants in 1 patient group

1

Experimental group

Description:

Fexofenadine

Treatment:

Drug: Fexofenadine